Skip to content
value.today

Arialys Therapeutics, Inc.

🇺🇸 La Jolla, California, USABiotechnologyFounded 2021
Total raised
$29 M
2 rounds on record
Latest round
$15 M
Jun 2025
First round on record
Nov 2022
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Arialys Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$15 MNo. 2$10 to $50 million

Arialys Therapeutics, Inc.: Raise no. 2, Jun 2025

Investors in this round

7 investors had bought by the notice of Jul 1, 2025: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $25 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Peter Flynn, Ph.D. · Executive Officer, Director
  • Ashish Xavier, Ph.D. · Director
  • Brian Slingsby, M.D., Ph.D., M.P.H. · Director
  • Ed Hurwitz · Director
  • Jay Lichter, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Flynn, Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 1, 2025. Read the notice at the SEC.

equitySEC
Nov 2022$14 MNo. 1$10 to $50 million

Arialys Therapeutics, Inc.: Raise no. 1, Nov 2022

Investors in this round

6 investors had bought by the notice of Dec 2, 2022: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $55 M offered; $41 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jay Lichter, Ph.D. · Executive Officer, Director
  • Tighe Reardon · Executive Officer
  • Brian Slingsby, M.D., Ph.D., M.P.H. · Director
  • Ed Hurwitz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total amount sold includes amounts paid in both cash and pursuant to conversion of indebtedness.”

Signed by Jay Lichter, Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 2, 2022. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Arialys Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2025).

    SEC Form D · Jul 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2025

That is all the official record says: Arialys Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Arialys Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 7 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Arialys Therapeutics, Inc.
NameRoleNamed in
Peter Flynn, Ph.D.Executive officerJul 2025
Jay Lichter, Ph.D.Executive officerDec 2022
Tighe ReardonExecutive officerDec 2022
Ashish Xavier, Ph.D.DirectorJul 2025
Brian Slingsby, M.D., Ph.D., M.P.H.DirectorJul 2025
Ed HurwitzDirectorJul 2025
Jay Lichter, Ph.D.DirectorJul 2025
Peter Flynn, Ph.D.DirectorJul 2025